|
(Exact name of registrant as specified in its charter)
|
|
|
|
||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
(Former name or former address, if changed since last report.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
-
|
|
Item 8.01
|
Other Events
|
Item 9.01 |
Exhibits.
|
Exhibit No. |
Description
|
99.1 |
ADMA Biologics, Inc. Press Release, dated March 7, 2022
|
104 |
Cover Page Interactive Data File (embedded with the Inline XBRL document)
|
March 7, 2022
|
ADMA Biologics, Inc.
|
||
|
|
||
|
|
||
|
By:
|
/s/ Brian Lenz
|
|
|
|
Name:
|
Brian Lenz
|
|
|
Title:
|
Executive Vice President and Chief Financial Officer
|
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end
)C?Q750]V@>']"O:,"<\3U9A6SF^!;8!R<^/
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MKVNY'>A!X'+3H!CKW'$)6%8:8!]3T]:,;
'7!AG-1G$S
M, I<^/J+<@-N9];7+Y9O7@PVWA19;GC2*?UT>G^DX'6JT&SY^DCA=G,*ZU )
M;_"5;!GS!0LJJAQ]&-:T%V 8$8Q(0)GQX+Z.